DYAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Dyazide patents expire, and when can generic versions of Dyazide launch?
Dyazide is a drug marketed by Glaxosmithkline Llc and is included in one NDA.
The generic ingredient in DYAZIDE is hydrochlorothiazide; triamterene. There are thirty-two drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; triamterene profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DYAZIDE?
- What are the global sales for DYAZIDE?
- What is Average Wholesale Price for DYAZIDE?
Summary for DYAZIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 134 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,440 |
| Drug Prices: | Drug price information for DYAZIDE |
| What excipients (inactive ingredients) are in DYAZIDE? | DYAZIDE excipients list |
| DailyMed Link: | DYAZIDE at DailyMed |
Recent Clinical Trials for DYAZIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| US Department of Veterans Affairs | |
| VA Office of Research and Development |
US Patents and Regulatory Information for DYAZIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | DYAZIDE | hydrochlorothiazide; triamterene | CAPSULE;ORAL | 016042-003 | Mar 3, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline Llc | DYAZIDE | hydrochlorothiazide; triamterene | CAPSULE;ORAL | 016042-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
